Teva says ‘very confident’ about growing generics business

Says “exciting time” for biosimilars. Sees ~$700M of net savings by 2027 with two thirds expected to be realized by 2026. Expects portfolio to “overdeliver” for full year. Says U.S. tariffs “absorbed” in FY25 non-GAAP outlook. Comments taken from Q2 earnings conference call.